title: Pharmacologically directed design of leukemia therapy.
abstract: The ability to accumulate and retain the active metabolite of Ara-C varies widely among patients. Our studies demonstrate a significant correlation between clinical response and the pharmacokinetics of Ara-CTP in leukemia cells during therapy. Knowledge of the cellular pharmacology of Ara-CTP has been used to optimize dose rates and to design combination treatment schedules. An understanding of the cellular pharmacodynamics of other drugs is likely to be a useful parameter for planning treatment protocols.
authors.affiliation: Department of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
authors.forename: W
authors.initials: W
authors.lastname: Plunkett
authors.forename: V
authors.initials: V
authors.lastname: Heinemann
authors.forename: E
authors.initials: E
authors.lastname: Estey
authors.forename: M
authors.initials: M
authors.lastname: Keating
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D001085:Arabinofuranosylcytosine Triphosphate / Q000378:metabolism*; D001088:Arabinonucleotides / Q000378:metabolism*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D007938:Leukemia / Q000378:metabolism* / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000378:metabolism; D008942:Mitoxantrone / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D001088:Arabinonucleotides; D003561:Cytarabine; D001085:Arabinofuranosylcytosine Triphosphate; D008942:Mitoxantrone